Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Payables: 2015-2024

Historic Payables for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $11.6 million.

  • Syndax Pharmaceuticals' Payables rose 182.28% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.9 million, marking a year-over-year increase of 49.99%. This contributed to the annual value of $11.6 million for FY2024, which is 16.72% up from last year.
  • As of FY2024, Syndax Pharmaceuticals' Payables stood at $11.6 million, which was up 16.72% from $10.0 million recorded in FY2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Payables peaked at $11.6 million during FY2024, and registered a low of $3.5 million during FY2020.
  • Over the past 3 years, Syndax Pharmaceuticals' median Payables value was $10.0 million (recorded in 2023), while the average stood at $8.6 million.
  • In the last 5 years, Syndax Pharmaceuticals' Payables slumped by 43.22% in 2020 and then skyrocketed by 128.99% in 2023.
  • Syndax Pharmaceuticals' Payables (Yearly) stood at $3.5 million in 2020, then spiked by 61.60% to $5.7 million in 2021, then declined by 23.27% to $4.3 million in 2022, then spiked by 128.99% to $10.0 million in 2023, then climbed by 16.72% to $11.6 million in 2024.